Reason(s) for refusal should be documented. 4) Physical and laboratory test findings a) Adequate hematologic function i) White blood cells ≥2,000/μ L ii) Neutrophils ≥1,500/μL (stable off any growth factor within 4 weeks of first study treatment administration) iii) Pl atelets ≥100× 103/μL (transfusion to achieve this level is not permitted within 2 weeks of first study tr eatment admin istration) iv) Hemoglobin ≥9.0 g/dL (transfusion to achieve this level is not permitted within 2 weeks of first study tr eatment administr ation) b) Adequate hepatic function i) ALT and AST ≤3× upper limit of normal (ULN) ii) Total bilirubin ≤1.5× ULN (except participants with Gilbert’s syndrome who must have normal direct bilirubin) c) Normal thyroid function or stable on hormone supplementation per i nvestigator assessment Revised Protocol No.: 04 Date: 31-May-2019 76 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS d) Serum creatinine ≤1.5× ULN or creatin ine clearance (CrCl) ≥40 mL/min (measured using the Cockcroft Gault formula below): Female CrCl = (140 - age in years) × weight in kg × 0.85 72 × serum creatinine in mg/dL Male CrCl = (140 - age in years) × weight in kg × 1.00 72 × serum creatinine in mg/dL e) Ability to comply with treatment, PK and PD sample collection, and required study followup. f) Participant re-enrollment: This study permits the re-enrollment of a participant who has discontinued the study as a pretreatment fail ure (eg, participant has not been treated).